MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Gilead Sciences Inc.

Uždarymo kaina

SektoriusSveikatos priežiūra

111.03 -0.63

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

110.68

Max

112.85

Pagrindiniai rodikliai

By Trading Economics

Pajamos

530M

1.8B

Pardavimai

29M

7.6B

P/E

Sektoriaus vid.

294.868

63.778

Pelnas, tenkantis vienai akcijai

1.9

Dividendų pajamingumas

2.82

Pelno marža

23.557

Darbuotojai

17,600

EBITDA

-655M

3.1B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+2.93% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

2.82%

2.39%

Kitas uždarbis

2025-04-24

Kitas dividendų mokėjimo data

2025-06-26

Kita Ex Dividend data

2025-06-13

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

18B

140B

Ankstesnė atidarymo kaina

111.66

Ankstesnė uždarymo kaina

111.03

Naujienos nuotaikos

By Acuity

9%

91%

10 / 386 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Gilead Sciences Inc. Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-02-11 21:17; UTC

Uždarbis

Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised

2024-12-19 15:25; UTC

Pagrindinės rinkos jėgos

Assembly Biosciences Shares Rise 19% After Gilead Investment, Funding

2024-12-19 13:38; UTC

Pagrindinės rinkos jėgos

Assembly Biosciences Gets $30.1 Million Equity Investment, Funding From Gilead

2024-11-06 22:25; UTC

Uždarbis

Gilead Sciences Post Higher 3Q Revenue, Raises Fiscal Year Guidance

2025-03-19 14:50; UTC

Svarbiausios naujienos

HIV Drug Makers Get Spooked by Trump Cuts, but Impact Looks Manageable -- Heard on the Street -- WSJ

2025-02-28 12:00; UTC

Svarbiausios naujienos

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

2025-02-11 22:13; UTC

Rinkos pokalbiai
Uždarbis

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

2025-02-11 21:06; UTC

Uždarbis

Gilead Beats Earnings Estimates on Strong HIV Sales -- Barrons.com

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Planning for Potential Launch of Lenacapavir for HIV PrEP in Summer 2025>GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Sees 2025 EPS $5.95-EPS $6.35 >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Raises Dividend to 79c Vs. 77c >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Sees 2025 Product Sales Excluding Veklury $26.8B - $27.2B>GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Raises Dividend 2.6%>GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Sees 2025 Adj EPS $7.70-Adj EPS $8.10 >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Sees 2205 Veklury Sales $1.4B>GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences Sees 2025 Sales $28.2B-$28.6B >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences 4Q >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences 4Q HCV Products Sales >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences 4Q Rev Up on HIV, Oncology, Liver Disease; Partially Offset by lower sales of Veklury (Remdesivir) >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences 4Q Adj EPS $1.90 >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences 4Q Rev $7.57B >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences 4Q EPS $1.42 >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences 4Q EPS $1.42 >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences 4Q Net $1.78B >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences 4Q Rev $7.6B >GILD

2025-02-11 21:02; UTC

Uždarbis

Gilead Sciences 4Q Adj EPS $1.90 >GILD

2025-01-10 10:30; UTC

Svarbiausios naujienos

Trump Says World Is Free-Riding on U.S. Health Spending. He Has a Point. -- WSJ

2024-12-29 08:00; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Buys $20.1 Million of Assembly Biosciences Stock -- Barrons.com

2024-12-19 13:23; UTC

Pagrindinės rinkos jėgos

Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead

2024-11-07 16:23; UTC

Uždarbis

Gilead Sprints To A Profit-Taking Zone After Riding Covid Drug To Beat And Raise -- IBD

Akcijų palyginimas

Kainos pokytis

Gilead Sciences Inc. Prognozė

Kainos tikslas

By TipRanks

2.93% į viršų

12 mėnesių prognozė

Vidutinis 115.33 USD  2.93%

Aukščiausias 140 USD

Žemiausias 90 USD

Remiantis 23 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Gilead Sciences Inc. kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

23 ratings

17

Pirkti

6

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

109.46 / 112.26Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Weak Bullish Evidence

Rinkos nuotaikos

By Acuity

10 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.